Khiron Life Sciences (Khiron Life Sciences) EBIT : $-23.80 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Khiron Life Sciences EBIT?

Khiron Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was $-2.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was $-23.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Khiron Life Sciences's annualized ROC % for the quarter that ended in Sep. 2022 was -49.46%. Khiron Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -61.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Khiron Life Sciences EBIT Historical Data

The historical data trend for Khiron Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences EBIT Chart

Khiron Life Sciences Annual Data

Trend

May12

May13

May14

May15

May16

May17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-0.03

-13.91

-28.54

-18.33

-25.90

Khiron Life Sciences Quarterly Data
	Nov17	Feb18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial															-2.57	-15.43	-4.16	-1.70	-2.52

Competitive Comparison of Khiron Life Sciences's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Khiron Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's EV-to-EBIT falls into.

Khiron Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.80 Mil.

Khiron Life Sciences (OTCPK:KHRWF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Khiron Life Sciences's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-10.508 * ( 1 - -3.63% )	/	( (21.722	+	22.308)	/ 2 )
=	-10.8894404	/	22.015
=	-49.46 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	31.427	-	5.161	-	( 4.544	-	max(0, 6.593	-	16.861	+	4.544	))
=	21.722

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.827	-	5.066	-	( 1.453	-	max(0, 7.205	-	13.739	+	1.453	))
=	22.308

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Khiron Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-10.068	/	( ( (10.693 + max(6.268, 0))	+	(9.855 + max(5.882, 0)) )	/	2 )
=	-10.068	/	( ( 16.961	+	15.737 )	/	2 )
=	-10.068	/	16.349
=	-61.58 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.318	+	7.368	+	1.508)	-	(5.161	+	0.123	+	0.642)
=	6.268

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.284	+	7.357	+	1.527)	-	(5.066	+	0.809	+	0.411)
=	5.882

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Khiron Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-23.798	/	0.000
	=	%

Khiron Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Khiron Life Sciences (Khiron Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRWF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5

Website

https://www.khiron.ca

Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.